Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart failure

References

• Nguyen KN, Ivar A, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol. 1997; 79: 115–9
   PubMed Web of Science ®Google Scholar
• Lip GYH, Gibbs CR. Does heart failure confer a hypercoagulable state?. J Am Coll Cardiol. 1999; 33: 1424–6
   PubMed Web of Science ®Google Scholar
• Chung I, Lip GYH. Platelets and heart failure. Eur Heart J. 2006; 27: 2623–31
   PubMed Web of Science ®Google Scholar
• Jafri SM, Ozawz T, Mammen E, Levine TB, Johnson C, Goldstein S. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J. 1993; 14: 205–12
   PubMed Web of Science ®Google Scholar
• Erne P, Wardle J, Sanders K, Lewis SM, Maseri A. Mean platelet volume and size distribution and their sensitivity to agonists in patients with coronary artery disease and congestive heart failure. Thromb Haemost. 1988; 59: 259–63
   PubMedGoogle Scholar
• Blann AD, Nadar SK, Lip GYH. The adhesion molecule and P-selectin and cardiovascular disease. Eur Heart J. 2003; 24: 2166–79
   PubMed Web of Science ®Google Scholar
• O'Connor C, Gurbel PA, Serebruany VL. Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. Am J Cardiol. 1999; 83: 1345–9
   PubMed Web of Science ®Google Scholar
• Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail. 2003; 5: 629–37
   PubMed Web of Science ®Google Scholar
• Gibbs CR, Blann AD, Watson RD, Lip GY. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic heart failure in sinus rhythm. Circulation. 2001; 103: 1746–51
   PubMed Web of Science ®Google Scholar
• Andre P, Hartwell D, Hrachovinova I, Saffaripour S, Wagner DD. Pro-coagulant state resulting from high levels of soluble P-selectin in blood. Proc Natl Acad Sci U S A. 2000; 97: 13835–40
   PubMed Web of Science ®Google Scholar
• Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P selectin but continue to circulate and function. Proc Natl Acad Sci U S A. 1996; 93: 11877–82
   PubMed Web of Science ®Google Scholar
• Ferroni P, Pulcinelli FM, Lenti L, Gazzaniga PP. Is soluble P-selectin determination a more reliable marker of in vivo platelet activation than CD62P flow cytometric analysis?. Thromb Haemost. 1999; 81: 472–3
   PubMed Web of Science ®Google Scholar
• Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin levels in atrial fibrillation. Stroke. 2002; 33: 1237–42
   PubMed Web of Science ®Google Scholar
• Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine diphosphate-induced platelet α-granule release. Blood. 1993; 82: 505–12
   PubMed Web of Science ®Google Scholar
• Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 2002; 88: 488–94
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J. 2004; 148: 157–64
   PubMed Web of Science ®Google Scholar
• Massie B, Krol W, Ammon S, Armstrong P, Cleland J, Collins J. Warfarin and Antiplatelet therapy in Chronic Heart Failure (WATCH), 9 March 2004. Available at: http://www.acc04online.acc.org/
   Google Scholar
• Schmitz G, Rothe G, Ruf A, Barlage S, Tschope D, Clemetson KJ, et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterization of platelet function. Thromb Haemost. 1998; 79: 885–96
   PubMed Web of Science ®Google Scholar
• Israels SJ, McMillan-Ward EM, Easton J, Robertson C, McNicol A. CD63 associates with the alphaIIb beta3 integrin-CD9 complex on the surface of activated platelets. Thromb Haemost. 2001; 85: 134–41
   PubMedGoogle Scholar
• Markovitz JH, Kulkarni K, Goldschmidt-Clermont P, Kiefe CI, Rustagi P, Sekar P, et al. Increased platelet activation and fibrinogen in Asian Indians. Eur Heart J. 1998; 19: 720–6
   PubMed Web of Science ®Google Scholar
• Negrescu EV, Sazonova LN, Baldenkov GN, Mukharliamov NM, Mazaev AV, Tkachuk VA. Relationship between the inhibition of receptor-induced increase in cytosolic free calcium concentration and the vasodilator effects of nitrates in patients with congestive heart failure. Int J Cardiol. 1990; 26: 175–84
   Google Scholar
• Pignatelli P, de Biase L, Lenti L, Tocci G, Brunelli A, Cangemi R, et al. Tumor necrosis factor-alpha as trigger of platelet activation in patients with heart failure. Blood. 2005; 106: 1992–4
   PubMed Web of Science ®Google Scholar
• Anfossi G, Trovati M. Role of catecholamines in platelet function: pathophysiological and clinical significance. Eur J Clin Invest. 1996; 26: 353–70
   PubMed Web of Science ®Google Scholar
• Dole VS, Bergeier W, Mitchell HA, Eichenberger SC, Wagner DD. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood. 2005; 106: 2334–9
   PubMed Web of Science ®Google Scholar
• Davi G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, et al. Diabetes mellitus, hypercholesterolaemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Circulation. 1997; 96: 69–75
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Kereiakes DJ, Serebruany VL. Soluble P-selectin is not a surrogate marker for platelet P-selectin: evidence from a multicenter chest pain study group. J Thromb Thrombolysis. 2001; 11: 155–62
   Google Scholar
• Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001; 103: 491–5
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Gattis WA, Fuzaylov SF, Gaulden L, Hasselblad V, Serebruany VL, et al. Evaluation of platelets in heart failure: Is platelet activity related to etiology, functional class, or clinical outcomes?. Am Heart J. 2002; 143: 1068–75
   PubMed Web of Science ®Google Scholar
• Chin BS, Blann AD, Gibbs CR, Chung NAY, Conway DS, Lip GY. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Invest. 2003; 33: 941–8
   PubMed Web of Science ®Google Scholar
• Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 2003; 5: 507–16
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Watson T, Lip GYH. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008; 51: 1829–43
   PubMed Web of Science ®Google Scholar